Codagenix reports promising findings for intranasal COVID vaccine

Codagenix announces promising findings for intranasal COVID vaccine TG23/iStock CIDRAP

Against the backdrop of a global push for new COVID vaccines that can provide broader and longer lasting protection, Codagenix announced that its live-attenuated intranasal vaccine candidate prompted robust humoral and cellular immunity in adults who took part in a phase 1 clinical trial.

The New York-based company detailed the findings for the vaccine, called CoviLiv, ahead of an October 13 presentation at the ID Week meeting in Boston. Codagenix is developing the vaccine with the Serum Institute of India, and a phase 3 efficacy trial is already underway as part of the World Health Organization (WHO) Solidarity vaccine trials.

...